This difference was likely due to the smaller number of indications in our analysis (23 vs. 69), the smaller patient sample size, a focus on several smaller tumors (i.e., ALK+), and using Flatiron Health to estimate tumor type-specific market shares, lines of therapy, and biomarker status. Here, ALK is linked to neoplasm.